Skip to main content
This site provides educational information only, not medical advice. Always consult a qualified healthcare provider.
Women's Health

HS and Pregnancy: A Complete Patient Guide

How hidradenitis suppurativa affects pregnancy, which treatments are safe, what to expect postpartum, and how to build a care team that supports both you and your baby.

Published: March 2026|Written by: War Against HS Team|Editorial Policy

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Medication decisions during pregnancy must be made in consultation with your dermatologist and obstetrician. Never start, stop, or change medications without professional guidance. Read full disclaimer.

Pregnancy is a time of profound physical and hormonal change, and for women living with hidradenitis suppurativa (HS), it raises important questions about disease activity, medication safety, and the health of both mother and child. Research on HS in pregnancy has grown significantly in recent years, providing clearer guidance for patients and clinicians. Understanding the hormonal factors that influence HS is also important context for pregnancy planning.

HS affects women at a 3:1 ratio compared to men, with peak onset during the reproductive years (ages 18-40). This means that pregnancy planning and management are central concerns for a large portion of the HS patient population. Understanding how HS behaves during pregnancy, which HS treatments are safe, and how to manage the postpartum period can help you navigate this time with greater confidence.

This guide draws on peer-reviewed research from the Journal of the American Academy of Dermatology, the British Journal of Dermatology, and European clinical guidelines to provide evidence-based information for patients and caregivers.

Disease Activity

How HS Changes During Pregnancy

The relationship between HS and pregnancy is complex and highly individual. A 2020 systematic review published in Acta Dermato-Venereologica found that disease activity during pregnancy is unpredictable: some women experience significant improvement, others report worsening, and some see no change at all.[1]

~30%
Improvement

Experience reduced flare frequency, particularly in the second and third trimesters, possibly due to elevated progesterone and immune modulation.

~40%
Worsening

Report increased disease activity, especially in the first trimester and postpartum period when hormonal shifts are most dramatic.

~30%
No Change

Experience stable disease activity throughout pregnancy with no significant change from their baseline.

Why Hormones Play a Central Role

HS is strongly influenced by androgens (male hormones present in both sexes), which stimulate the hair follicle activity that drives HS lesion formation. During pregnancy, the hormonal environment shifts dramatically. Estrogen and progesterone rise significantly, while androgen activity is relatively suppressed in some women - which may explain improvement in some cases.

However, the postpartum period brings a rapid drop in estrogen and progesterone, which can trigger significant HS flares. Many women report their worst HS episodes in the weeks following delivery. This is an important period to plan for with your care team.

For a deeper understanding of how hormones affect HS, see our dedicated guide: HS and Hormones: Understanding the Connection.

Research Findings

Pregnancy Outcomes and HS

A 2021 population-based cohort study published in the British Journal of Dermatology examined pregnancy outcomes in women with HS compared to the general population.[5] The findings highlight the importance of proactive management:

!

Preterm Birth

Women with HS had a modestly elevated risk of preterm birth compared to controls. Severe, uncontrolled inflammation is thought to contribute to this risk through systemic inflammatory pathways.

!

Gestational Diabetes

HS is associated with insulin resistance and metabolic syndrome. Women with HS have a higher baseline risk of gestational diabetes, making glucose monitoring during pregnancy particularly important.

!

Cesarean Delivery

HS lesions in the groin, inner thighs, or perineal area may complicate vaginal delivery. Discuss delivery planning with your obstetric team early in pregnancy.

!

Postpartum Flares

The postpartum period carries a high risk of HS flares due to rapid hormonal changes. Planning for this period with your dermatologist before delivery is strongly recommended.

Important Context

These risks are modest in absolute terms and many women with HS have healthy pregnancies and healthy babies. The key is proactive management: working with a multidisciplinary team, maintaining disease control where possible, and planning for the postpartum period. HS does not prevent pregnancy or make pregnancy inherently dangerous.

Treatment Safety

Safe Treatments During Pregnancy

Treatment decisions during pregnancy require careful balancing of the risks of active HS disease against the potential risks of medications to the developing fetus. The following guidance is based on current clinical guidelines from the American Academy of Dermatology and the European Academy of Dermatology and Venereology.[2][7]

Generally Considered Safe

Topical clindamycin 1%: First-line topical antibiotic. Minimal systemic absorption. Considered safe throughout pregnancy.
Warm compresses: Non-pharmacological. Safe and effective for pain relief and lesion management.
Gentle cleansing: Chlorhexidine-based washes at appropriate dilution. See our Hygiene Guide for protocols.
Intralesional corticosteroids: Short-term use for acute flares. Discuss with your dermatologist regarding timing and frequency.
Incision and drainage: Procedural management of acute abscesses. Generally safe when performed by a trained clinician.

Use With Caution (Discuss With Your Physician)

Adalimumab (Humira): May be used in the first and second trimesters for severe HS when benefits outweigh risks. Crosses the placenta in the third trimester - typically discontinued by week 30-32. Discuss with your rheumatologist or dermatologist.
Oral clindamycin: Generally considered low risk but systemic exposure is higher than topical. Use only when clearly indicated.
Zinc supplementation: Some evidence for benefit in HS. Generally considered safe in recommended doses during pregnancy.
Contraindicated

Medications to Avoid During Pregnancy

Several medications commonly used for HS are contraindicated during pregnancy due to known teratogenic effects (ability to cause birth defects) or other fetal risks. If you are planning a pregnancy, discuss transitioning off these medications with your dermatologist well in advance.

MedicationRiskWashout Period
Tetracyclines (doxycycline, minocycline)Tooth discoloration, bone growth impairment in fetusDiscontinue before conception
Retinoids (isotretinoin, acitretin)Severe teratogen - causes major birth defects1 month (isotretinoin), 3 years (acitretin)
MethotrexateTeratogen, abortifacient3-6 months before conception
SpironolactoneAnti-androgen effects may feminize male fetusDiscontinue before conception
CyclosporineImmunosuppression, potential fetal growth restrictionDiscuss with physician

This list is not exhaustive. Always review all medications with your dermatologist and obstetrician before and during pregnancy. For a full overview of HS treatment options, see our HS Treatments Guide.

Postpartum Care

Postpartum Management and Breastfeeding

Managing Postpartum Flares

The postpartum period is one of the highest-risk times for HS flares. The rapid drop in estrogen and progesterone after delivery, combined with physical stress, sleep deprivation, and the demands of newborn care, can trigger significant disease activity. Planning ahead is essential.

Before Delivery

  • - Discuss postpartum flare management plan with your dermatologist
  • - Have topical clindamycin and dressings stocked at home
  • - Identify a support person who can help with wound care
  • - Know when to contact your dermatologist urgently

After Delivery

  • - Resume pre-pregnancy medications as soon as cleared by your physician
  • - Monitor for new lesions in the first 4-6 weeks
  • - Prioritize sleep and stress management where possible
  • - Attend your 6-week dermatology follow-up

Breastfeeding and HS Medications

Breastfeeding decisions for women with HS require careful consideration of medication transfer into breast milk. Topical clindamycin is generally considered compatible with breastfeeding due to minimal systemic absorption. Adalimumab has limited data but is thought to have low transfer into breast milk and may be compatible with breastfeeding in some cases.

Tetracyclines, retinoids, and methotrexate are contraindicated during breastfeeding. The LactMed database (National Institutes of Health) is an excellent resource for checking the safety of specific medications during lactation.

NIH LactMed Database - Medication Safety During Breastfeeding
Care Planning

Building Your Multidisciplinary Care Team

Managing HS during pregnancy requires coordination between multiple specialists. Ideally, your care team should be assembled before conception or as early as possible in the first trimester.

Dermatologist

Manages HS disease activity, adjusts medications for pregnancy safety, and provides wound care guidance. Should be informed of your pregnancy as early as possible.

Obstetrician / Maternal-Fetal Medicine

Manages overall pregnancy health, monitors for complications, and coordinates with your dermatologist on medication decisions. A maternal-fetal medicine specialist may be appropriate for complex cases.

Mental Health Professional

HS has significant psychological impact, and pregnancy adds additional emotional demands. A therapist or counselor familiar with chronic illness can be invaluable.

Registered Dietitian

Anti-inflammatory dietary strategies may help reduce HS disease activity. A dietitian can help you optimize nutrition for both HS management and pregnancy health.

Finding an HS Specialist

Not all dermatologists have experience managing HS during pregnancy. Use the AAD's Find a Dermatologist tool to locate a specialist, and ask specifically about their experience with HS in pregnancy.

Find an HS-Experienced Dermatologist
FAQ

Frequently Asked Questions

References

[1]Kromann CB, et al. Hidradenitis suppurativa during pregnancy: a systematic review. Acta Derm Venereol. 2020;100(3). PubMed
[2]Alikhan A, et al. North American clinical management guidelines for hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(1):76-90. PubMed
[3]Gulliver W, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-351. PubMed
[4]Kimball AB, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. PubMed
[5]Jfri A, et al. Hidradenitis suppurativa and pregnancy outcomes: a population-based cohort study. Br J Dermatol. 2021;185(2):390-396. PubMed
[6]American Academy of Dermatology. Hidradenitis suppurativa: diagnosis and treatment. AAD Clinical Guidelines. 2019. PubMed
[7]Zouboulis CC, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644. PubMed
[8]Marzano AV, et al. Hidradenitis suppurativa and the metabolic syndrome. Br J Dermatol. 2018;178(1):e1-e3. PubMed

References are provided for transparency. This article is for educational purposes only. See our Editorial Policy and Content & Research Process for sourcing standards.